You are here: » News » Newsdetails:

Visus Expands Ophthalmic Drug Portfolio for Corneal Wound Healing, Glaucoma and AMD

Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, unveiled additional ophthalmic drug candidates (VT-201) with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD).